Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
CONCLUSIONS: A substantial proportion of PD-L1 negative, TNBC patients showed complete/partial loss of MMR and/or high TILs indicating that supplementing PD-L1 examination with these biomarkers may identify TNBC-patients that may be selected for immunotherapy.PMID:34530255 | DOI:10.1016/j.prp.2021.153606
Source: Pathology, Research and Practice - Category: Pathology Authors: Demet Özcan Johanne Lade-Keller Trine Tramm Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Gastroschisis Repair | Immunotherapy | Pathology